Authors

• Ali Niak (ORCID: https://orcid.org/0000-0003-3404-3212)
• David J. Graham (ORCID: https://orcid.org/0000-0002-7469-4047)
• Yueqin Zhao
• Kate Gelperin
• Michael Wernecke (ORCID: https://orcid.org/0000-0001-9553-3122)
• Olivia Easley
• Hai Lyu (ORCID: https://orcid.org/0000-0001-5041-7902)
• Marina Zemskova
• Tae Hyun Jung (ORCID: https://orcid.org/0000-0001-8188-3420)
• Steven T. Bird (ORCID: https://orcid.org/0000-0001-7976-3462)
• Yoganand Chillarige (ORCID: https://orcid.org/0000-0002-8020-6839)
• Rekha Kambhampati
• Kushal Naik (ORCID: https://orcid.org/0000-0002-8017-9228)
• Elizabeth R. Smith (ORCID: https://orcid.org/0000-0003-3415-1061)
• Aliza Thompson
• Jeffrey A. Kelman

Institutions

• United States Food and Drug Administration (US)
• Center for Drug Evaluation and Research (US)
• Acumen (United States) (US)
• Centers for Medicare and Medicaid Services (US)

Publication Details

Journal

Annals of Internal Medicine

Published

2024-11-18

DOI

https://doi.org/10.7326/m24-0013

Citations

14

Primary Topic

Parathyroid Disorders and Treatments

Type

article

Field-Weighted Citation Impact

4.75